Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have experienced rapid growth in recent years as treatments for type 2 diabetes mellitus and obesity. These medications offer promising benefits, including weight loss and improved glycemic control; however, their implications for reproductive health warrant attention. While tirzepatide has been shown to impact absorption of oral contraceptives due to delayed gastric emptying, other GLP-1RAs do not appear to have clinically significant interactions with oral contraception. Fertility outcomes may improve with GLP-1RAs and dual GLP-1/GIP agonists due to weight loss and related metabolic benefits. Despite their widespread use, data on GLP-1RAs in pregnancy and lactation remain limited, leaving significant gaps in guidance for clinicians. This review synthesizes current literature on GLP-1RAs to highlight reproductive health considerations, including their potential impacts on contraception, fertility, pregnancy, and lactation. Greater awareness and understanding of these factors can support informed decision-making and optimize care for individuals using GLP-1RAs.

Keywords

glucagon-like peptide-1 receptor agonist contraception fertility pregnancy lactation reproductive health

Get full access to this article

View all access options for this article.

References

Byetta. Prescribing Information. Bristol-Myers Squibb Company; 2014. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021773s036lbl.pdf

Collins

Costello

. Glucagon-like peptide-1 receptor agonists. In: StatPearls. Treasure Island (FL), 29. StatPearls Publishing; 2024.

Davidson

. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108(3 Suppl):33-41. doi:10.1016/j.amjcard.2011.03.046

Vilsbøll

Christensen

Junker

Knop

Gluud

. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi:10.1136/bmj.d7771

Garber

. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279-S284. doi:10.2337/dc11-s231

Gallwitz

. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol. 2011;203:53-74. doi:10.1007/978-3-642-17214-4_3

Okerson

Chilton

. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146-e155. doi:10.1111/j.1755-5922.2010.00256.x

Andersen

Lund

Knop

Vilsbøll

. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390-403. doi:10.1038/s41574-018-0016-2

Taal

Selby

. Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT trials. Am J Kidney Dis. 2025;85(1):115-118. doi:10.1053/j.ajkd.2024.08.002

10.

Yashi

Daley

. Obesity and Type 2 Diabetes. StatPearls. Treasure Island (FL). StatPearls Publishing; 2023.

11.

Grant

Sandelson

Agyemang-Prempeh

Zalin

. Managing obesity in people with type 2 diabetes. Clin Med. 2021;21(4):e327. doi:10.7861/clinmed.2021-0370

12.

National Diabetes Statistics Report. Centers for Disease Control and Prevention. Accessed January 13, 2023.https://www.cdc.gov/diabetes/php/data-research/index.html

13.

One billion people globally estimated to be living with obesity by 2030. International Diabetes Federation. 2023. Accessed January 13, 2024.https://idf.org/news/one-billion-people-globally-estimated-to-be-living-with-obesity-by-2030/

14.

Ciarambino

Crispino

Leto

Mastrolorenzo

Para

Giordano

. Influence of gender in diabetes mellitus and its complication. Int J Mol Sci. 2022;23(16):8850. doi:10.3390/ijms23168850

15.

Obesity and Overweight. World Health Organization. Accessed February 22, 2024.https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

16.

Diabetes. World health organization. Accessed January 13, 2024.https://www.who.int/news-room/facts-in-pictures/detail/diabetes

17.

Diabetes in Young People Is on the Rise. Centers for Disease Control and Prevention. Accessed January 13, 2024.https://www.cdc.gov/diabetes/data-research/research/young-people-diabetes-on-rise.html?CDC_AAref_Val=https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fresources-publications%2Fresearch-summaries%2Fdiabetes-young-people.html

18.

El Kishawi

Soo

Abed

Muda

WAMW

. Prevalence and predictors of overweight and obesity among women in the Gaza strip-Palestine: a cross-sectional study. BMC Public Health. 2020;20(1):864. doi:10.1186/s12889-020-08966-1

19.

Cooper

Gupta

Moustafa

Chao

. Sex/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep. 2021;10(4):458-466. doi:10.1007/s13679-021-00453-x

20.

Azeez

Kulkarni

Kuklina

Kim

Cox

. Hypertension and diabetes in non-pregnant women of reproductive age in the United States. Prev Chronic Dis. 2019;16:E146. doi:10.5888/pcd16.190105

21.

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics . ACOG practice bulletin No. 201: pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960

22.

Diabetes during Pregnancy. Centers for Disease Control and Prevention. Accessed January 13, 2024.https://www.cdc.gov/maternal-infant-health/pregnancy-diabetes/index.html

23.

Dağ

ZÖ

Dilbaz

. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111-117. doi:10.5152/jtgga.2015.15232

24.

Palmer

Bakos

Fullston

Lane

. Impact of obesity on male fertility, sperm function and molecular composition. Spermatogenesis. 2012;2(4):253-263. doi:10.4161/spmg.21362

25.

Excess weight may affect sperm production, reduce fertility in men. Harvard T.H. Chan School of Public Health. Accessed December 7, 2024.https://hsph.harvard.edu/news/excess-weight-sperm-fertility/

26.

Peterson

Pollom

. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl. 2010;64(s167):35-43. doi:10.1111/j.1742-1241.2010.02498.x

27.

Curtis

Nguyen

Tepper

, et al. U.S. Selected practice recommendations for contraceptive use, 2024. MMWR Recomm Rep (Morb Mortal Wkly Rep). 2024;73(3):1-77. doi:10.15585/mmwr.rr7303a1

28.

Hanker

. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol. 1990;163(6 Pt 2):2204-2207. doi:10.1016/0002-9378(90)90562-l

29.

Latif

Lambrinos

Patel

Rodriguez

. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP-1RAs). In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2024.

30.

Mounjaro. Prescribing Information. Eli Lilly and Company; 2024. Accessed January 14 2024.https://uspl.lilly.com/mounjaro/mounjaro.html#pi

31.

Zepbound. Prescribing Information. Eli Lilly and Company; 2024. Accessed January 14 2024.https://pi.lilly.com/us/zepbound-uspi.pdf

32.

Daniels

Abma

. Current contraceptive status among women aged 15-49: United States, 2017-2019. NCHS Data Brief. 2020;388:1-8.

33.

Nguyen

Curtis

Tepper

, et al. U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep (Morb Mortal Wkly Rep). 2024;73(4):1-126. doi:10.15585/mmwr.rr7304a1

34.

Trulicity. Prescribing Information. Eli Lilly and Company; 2014. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf

35.

Ozempic. Prescribing information. Novo Nordisk. 2017. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf

36.

Wegovy. Prescribing information. Novo Nordisk. 2022. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf

37.

Bydureon. Prescribing information. AstraZeneca. 2017. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf

38.

Adlyxin. Prescribing information. Sanofi. 2016. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf

39.

Victoza. Prescribing information. Novo Nordisk. 2017. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf

40.

Soliquia. Prescribing information. Sanofi. 2016. Accessed January 14, 2024.https://products.sanofi.us/Soliqua100-33/Soliqua100-33.pdf

41.

Saxenda. Prescribing information. Novo Nordisk. 2014. Accessed January 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf

42.

Rybelsus. Prescribing information. Novo Nordisk. 2023. Accessed May 19, 2025.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf

43.

Jacobsen

Vouis

Hindsberger

Zdravkovic

. Treatment with liraglutide—a once‐daily GLP‐1 analog—does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011;51(12):1696-1703.

44.

de la Peña

Cui

Geiser

Loghin

. No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide. Clin Pharmacokinet. 2017;56(11):1415-1427.

45.

Kapitza

Nosek

Jensen

Hartvig

Jensen

Flint

. Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497-504.

46.

Hedrington

Davis

. Oral semaglutide for the treatment of type 2 diabetes. Expet Opin Pharmacother. 2019;20(2):133-141. doi:10.1080/14656566.2018.1552258

47.

Vergnaud

Billingsley

. Ozempic babies? what research says about semaglutide. GLP-1 Agonists. 2024. https://www.goodrx.com/classes/glp-1-agonists/semaglutide-and-fertility. Accessed June 8, 2024.

48.

Klein

. An Ozempic baby boom? some GLP-1 users report unexpected pregnancies. 2024. https://www.washingtonpost.com/wellness/2024/04/05/ozempic-babies-weight-loss-fertility/. Accessed April 6, 2024.

49.

Scherer

. Caution urged for obesity drugs and birth control pills. Medscape. 2023. https://www.medscape.com/s/viewarticle/997498?ecd=WNL_mdpls_231024_mscpedit_pharm_etid5984046&uac=344188BN&spon=30&impID=5984046&form=fpf. Accessed January 13, 2024.

50.

Skelley

Swearengin

York

Glover

. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc. 2023;64(23):204-211.e4. doi:10.1016/j.japh.2023.10.037

51.

Slynd. Prescribing information. Exeltis USA. 2019. Accessed May 19,2025.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf

52.

Sahu

Pajai

. The impact of obesity on reproductive health and pregnancy outcomes. Cureus. 2023;15(11):e48882. doi:10.7759/cureus.48882

53.

Varnum

Pozzi

Deebel

, et al. Impact of GLP-1 agonists on male reproductive health-a narrative review. Medicina (Kaunas). 2023;60(1):50. doi:10.3390/medicina60010050

54.

Pavli

Triantafyllidou

Kapantais

Vlahos

Valsamakis

. Infertility improvement after medical weight loss in women and men: a review of the literature. Int J Mol Sci. 2024;25(3):1909. doi:10.3390/ijms25031909

55.

Elkind-Hirsch

Marrioneaux

Bhushan

Vernor

Bhushan

. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670-2678.

56.

Mai

Zheng

Zhang

. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022;306(5):1711-1721.

57.

Wang

Zhan

, et al. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides. 2021;145:170624. doi:10.1016/j.peptides.2021.170624

58.

Nylander

Frøssing

Clausen

Kistorp

Faber

Skouby

. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121-127.

59.

Moffett

Naughton

. Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides. 2020;125:170233.

60.

Minis

Stanford

Mahalingaiah

. Glucagon-like peptide-1 receptor agonists and safety in the preconception period. Curr Opin Endocrinol Diabetes Obes. 2023;30(6):273-279. doi:10.1097/MED.0000000000000835

61.

Muller

DRP

Stenvers

Malekzadeh

Holleman

Painter

Siegelaar

. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol. 2023;14:1215356. doi:10.3389/fendo.2023.1215356

62.

Cesta

Rotem

Bateman

, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144-152. doi:10.1001/jamainternmed.2023.6663

63.

Williams

Pomeroy

Pop-Busui

, et al. Case report: exenatide use during pregnancy. Endocrinololgist. 2009;19(30):119-121. doi:10.1097/TEN.0b013e3181a5875e

64.

Doğan

ŞE

Kuşkonmaz

ŞM

Koc

Aypar

Çulha

. Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings. Endocr, Metab Immune Disord: Drug Targets. 2024;24(10):1237-1239. doi:10.2174/0118715303252109231023115112

65.

Petersen

Knop

Christensen

. Lixisenatide for the treatment of type 2 diabetes. Drugs Today. 2013;49(9):537-553. doi:10.1358/dot.2013.49.9.2020940

66.

Alghamdi

Alsaeddi

Malki

Alsaedi

. A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy. Cureus. 2023;15(9):e44644. doi:10.7759/cureus.44644

67.

Patel

Healy

. Positive pregnancy outcome following first trimester dulaglutide exposure in a women with type 2 diabetes and PCOS: a case report. J Diabet Res Rev Rep. 2024;6(1):1-4. doi:10.47363/JDRR/2024(6)178

68.

Skov

Mandic

Nyborg

. Semaglutide and pregnancy. Int J Gynaecol Obstet. 2023;163(2):699-700. doi:10.1002/ijgo.15092

69.

Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006. https://www.ncbi.nlm.nih.gov/books/NBK500979/

70.

Radcliffe

. About 13% of U.S. Adults Have Tried a GLP-1 Drug like Ozempic. Healthline. 2024. https://www.healthline.com/health-news/how-common-are-glp-1-drugs-like-ozempic-13-of-u-s-adults-have-used-them#:∼:text=One_in-eight_American-adults_have_used_a,younger_adults_than_those_65_years_or_older. (Accessed June 15, 2024).

71.

Jensen

Ryan

Apovian

, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102-S138. doi:10.1161/01.cir.0000437739.71477.ee

72.

Garvey

Mechanick

Brett

, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. doi:10.4158/EP161365.GL